Skip to Content

Bio-Techne Corp TECH

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Bio-Techne Starts Fiscal 2022 With Strong Growth Offset by Labor-Related Margin Pressure

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Narrow-moat Bio-Techne had a strong start to fiscal 2022, reporting organic sales growth of 21% and adjusted EPS increasing to $1.83 from $1.43 last year. We are maintaining our $320 fair value estimate and are not materially changing our long-term expectations. The shares trade well above our fair value estimate--at a 55% premium--even following the 4% decline in Nov. 2 trading.

Read Full Analysis

Company Profile

Business Description

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Contact
614 McKinley Place N.E.
Minneapolis, MN, 55413
T +1 612 379-8854
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2021
Fiscal Year End Jun 30, 2021
Stock Type Aggressive Growth
Employees 2,600